| Literature DB >> 26967670 |
Caitlin G Howe1, Xinhua Liu, Megan N Hall, Vesna Slavkovich, Vesna Ilievski, Faruque Parvez, Abu B Siddique, Hasan Shahriar, Mohammad N Uddin, Tariqul Islam, Joseph H Graziano, Max Costa, Mary V Gamble.
Abstract
BACKGROUND: Exposure to inorganic arsenic is associated with numerous adverse health outcomes, with susceptibility differing by sex. Although evidence from in vitro studies suggests that arsenic alters post-translational histone modifications (PTHMs), evidence in humans is limited.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26967670 PMCID: PMC4977054 DOI: 10.1289/ehp.1510412
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Baseline characteristics of FACT participants with at least one %PTHM measure and complete information for variables included in regression models.
| Characteristic | Whole sample ( | Men ( | Women ( | |
|---|---|---|---|---|
| Age (years) | 39 (24–54) | 42 (25–54) | 37 (24–54) | < 0.01 |
| BMI (kg/m2) | 19.3 (13.9–31.6) | 18.7 (15.4–27.9) | 20.0 (13.9–31.6) | < 0.01 |
| uCr (μg/L) | 48 (6–252) | 53 (6–252) | 45 (6–233) | 0.03 |
| bAs (μg/L) | 8.8 (1.0–80.2) | 9.6 (2.5–52.0) | 7.9 (1.0–80.2) | 0.05 |
| uAs (μg/L) | 121 (11–1,770) | 123 (11–1,770) | 121 (11–1,320) | 0.67 |
| uAsCr (μg/g uCr) | 257 (35–2,200) | 242 (65–1,480) | 287 (35–2,200) | 0.03 |
| %H3K36me2 | 1.45 (0.68–6.87) | 1.45 (0.68–4.00) | 1.43 (1.00–6.87) | 0.47 |
| %H3K36me3 | 1.61 (0.48–6.44) | 1.57 (0.48–4.09) | 1.62 (0.52–6.44) | 0.18 |
| %H3K79me2 | 1.26 (0.29–9.46) | 1.26 (0.29–9.46) | 1.25 (0.29–9.41) | 0.69 |
| Folate < 9 nmol/L | 74 (23.3) | 46 (28.6) | 28 (18.0) | 0.03 |
| B12 < 151 pmol/L | 77 (24.3) | 39 (24.2) | 38 (24.4) | 0.98 |
| Ever smoker | 93 (29.3) | 91 (56.5) | 2 (1.3) | < 0.01 |
| Ever betel | 87 (27.4) | 48 (29.8) | 39 (25.0) | 0.34 |
| Education > 5 years | 77 (22.4) | 33 (20.5) | 38 (24.4) | 0.41 |
| Abbreviations: bAs, blood arsenic; BMI, body mass index; FACT, Folic Acid and Creatine Trial; H3K36me2, dimethylation of lysine 36 of histone H3; H3K36me3, trimethylation of lysine 36 of histone H3; H3K79me2, dimethylation of lysine 79 of histone H3; PTHM, post-translational histone modification; uAs, urinary arsenic; uAsCr, urinary arsenic adjusted for urinary creatinine; uCr, urinary creatinine. | ||||
Estimated regression coefficients and 95% confidence intervals for associations between baseline measures of arsenic exposure and %PTHMs in FACT participants.
| %PTHM/arsenic exposure | Whole sample | Men | Women | |
|---|---|---|---|---|
| %H3K36me2 | ||||
| bAs | 0.02 (–0.05, 0.09) | 0.12 (–0.00, 0.24) | –0.04 (–0.12, 0.04) | 0.04 |
| Adjusted bAs | 0.02 (–0.05, 0.09) | 0.10 (–0.02, 0.22) | –0.03 (–0.11, 0.05) | 0.08 |
| uAsCr | 0.01 (–0.05, 0.08) | 0.13 (0.02, 0.24)* | –0.05 (–0.12, 0.02) | < 0.01 |
| Adjusted uAsCr | 0.02 (–0.05, 0.08) | 0.12 (0.01, 0.23)* | –0.05 (–0.12, 0.02) | 0.01 |
| %H3K36me3 | ||||
| bAs | –0.03 (–0.10, 0.04) | 0.06 (–0.04, 0.16) | –0.08 (–0.17, 0.01) | 0.04 |
| Adjusted bAs | –0.02 (–0.09, 0.05) | 0.05 (–0.04, 0.15) | –0.07 (–0.16, 0.02) | 0.07 |
| uAsCr | –0.01 (–0.07, 0.05) | 0.07 (–0.02, 0.16) | –0.06 (–0.14, 0.02) | 0.04 |
| Adjusted uAsCr | 0.00 (–0.06, 0.06) | 0.07 (–0.02, 0.16) | –0.05 (–0.14, 0.03) | 0.05 |
| %H3K79me2 | ||||
| bAs | 0.04 (–0.05, 0.12) | 0.04 (–0.09, 0.17) | 0.03 (–0.08, 0.14) | 0.91 |
| Adjusted bAs | 0.03 (–0.05, 0.12) | 0.04 (–0.09, 0.17) | 0.04 (–0.08, 0.15) | 0.95 |
| uAsCr | 0.02 (–0.06, 0.09) | 0.05 (–0.07, 0.17) | 0.00 (–0.10, 0.10) | 0.53 |
| Adjusted uAsCr | 0.01 (–0.06, 0.09) | 0.04 (–0.08, 0.17) | 0.01 (–0.10, 0.11) | 0.65 |
| Abbreviations: bAs, blood arsenic; FACT, Folic Acid and Creatine Trial; H3K36me2, dimethylation of lysine 36 of histone H3; H3K36me3, trimethylation of lysine 36 of histone H3; H3K79me2, dimethylation of lysine 79 of histone H3; PTHM, post-translational histone modification; uAsCr, urinary arsenic adjusted for urinary creatinine. | ||||
Within-person changes in %PTHMs from baseline to week 12 for FACT participants in the placebo group.
| %PTHM | Whole sample | Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Median (IQR) | ||||||||
| %H3K36me2 | 56 | –0.15 (–0.43, 0.11) | < 0.01 | 27 | –0.07 (–0.44, 0.16) | 0.14 | 29 | –0.17 (–0.37, 0.04) | < 0.01 | 0.62 |
| %H3K36me3 | 55 | 0.02 (–0.23, 0.30) | 0.61 | 28 | 0.05 (–0.23, 0.47) | 0.35 | 27 | 0.02 (–0.22, 0.12) | 0.93 | 0.35 |
| %H3K79me2 | 56 | –0.05 (–0.24, 0.04) | 0.07 | 29 | –0.03 (–0.28, 0.09) | 0.36 | 27 | –0.05 (–0.18, 0.04) | 0.10 | 0.88 |
| Abbreviations: FACT, Folic Acid and Creatine Trial; H3K36me2, dimethylation of lysine 36 of histone H3; H3K36me3, trimethylation of lysine 36 of histone H3; H3K79me2, dimethylation of lysine 79 of histone H3; IQR, interquartile range; PTHM, post-translational histone modification. | ||||||||||